Compare Procter & Gamble Health with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs STERLING BIOTECH - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH STERLING BIOTECH PROCTER & GAMBLE HEALTH/
STERLING BIOTECH
 
P/E (TTM) x 51.5 -0.4 - View Chart
P/BV x 4.7 0.0 32,708.6% View Chart
Dividend Yield % 10.2 0.0 -  

Financials

 PROCTER & GAMBLE HEALTH   STERLING BIOTECH
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
STERLING BIOTECH
Dec-13
PROCTER & GAMBLE HEALTH/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs3,54911 33,800.0%   
Low Rs1,3013 38,273.5%   
Sales per share (Unadj.) Rs511.426.8 1,907.9%  
Earnings per share (Unadj.) Rs61.3-15.0 -409.8%  
Cash flow per share (Unadj.) Rs74.0-5.5 -1,354.9%  
Dividends per share (Unadj.) Rs440.000-  
Dividend yield (eoy) %18.10-  
Book value per share (Unadj.) Rs927.854.9 1,690.5%  
Shares outstanding (eoy) m16.60267.87 6.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.70.3 1,828.9%   
Avg P/E ratio x39.6-0.5 -8,515.5%  
P/CF ratio (eoy) x32.8-1.3 -2,575.5%  
Price / Book Value ratio x2.60.1 2,064.1%  
Dividend payout %717.90-   
Avg Mkt Cap Rs m40,2571,862 2,162.4%   
No. of employees `0001.11.4 83.8%   
Total wages/salary Rs m1,313547 240.1%   
Avg. sales/employee Rs Th7,486.75,303.3 141.2%   
Avg. wages/employee Rs Th1,157.6403.8 286.6%   
Avg. net profit/employee Rs Th897.2-2,959.0 -30.3%   
INCOME DATA
Net Sales Rs m8,4907,181 118.2%  
Other income Rs m24443 572.5%   
Total revenues Rs m8,7347,223 120.9%   
Gross profit Rs m1,482947 156.5%  
Depreciation Rs m2112,543 8.3%   
Interest Rs m04,377 0.0%   
Profit before tax Rs m1,514-5,931 -25.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m563-1,924 -29.2%   
Profit after tax Rs m1,017-4,007 -25.4%  
Gross profit margin %17.513.2 132.3%  
Effective tax rate %37.132.4 114.5%   
Net profit margin %12.0-55.8 -21.5%  
BALANCE SHEET DATA
Current assets Rs m15,34314,335 107.0%   
Current liabilities Rs m1,96049,809 3.9%   
Net working cap to sales %157.6-494.0 -31.9%  
Current ratio x7.80.3 2,719.7%  
Inventory Days Days49403 12.1%  
Debtors Days Days28171 16.7%  
Net fixed assets Rs m1,20955,432 2.2%   
Share capital Rs m166268 62.0%   
"Free" reserves Rs m15,23513,935 109.3%   
Net worth Rs m15,40114,701 104.8%   
Long term debt Rs m09,478 0.0%   
Total assets Rs m17,59573,988 23.8%  
Interest coverage xNM-0.4-  
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.50.1 497.2%   
Return on assets %5.80.5 1,154.4%  
Return on equity %6.6-27.3 -24.2%  
Return on capital %10.3-6.4 -159.6%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m1,6361,860 88.0%   
Fx outflow Rs m4,36825 17,549.6%   
Net fx Rs m-2,7321,835 -148.9%   
CASH FLOW
From Operations Rs m-1,3041,719 -75.9%  
From Investments Rs m12,697-3,148 -403.3%  
From Financial Activity Rs m-3011,426 -21.1%  
Net Cashflow Rs m11,093-3 -326,261.8%  

Share Holding

Indian Promoters % 0.0 33.9 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 0.0 -  
FIIs % 1.0 9.9 10.1%  
ADR/GDR % 0.0 16.9 -  
Free float % 29.1 39.3 74.0%  
Shareholders   28,591 21,482 133.1%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   PFIZER  ABBOTT INDIA  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare PROCTER & GAMBLE HEALTH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

MERCK LTD Announces Quarterly Results (2QFY19); Net Profit Up 29.8% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, MERCK LTD has posted a net profit of Rs 411 m (up 29.8% YoY). Sales on the other hand came in at Rs 2 bn (down 27.7% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Sep 13, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 5-YR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS